Defence Therapeutics Inc
CNSX:DTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Defence Therapeutics Inc
Net Income (Common)
Defence Therapeutics Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Defence Therapeutics Inc
CNSX:DTC
|
Net Income (Common)
-CA$3.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Net Income (Common)
-$146.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Net Income (Common)
-CA$12.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-91%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Net Income (Common)
$287.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Net Income (Common)
-$168.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-112%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Net Income (Common)
-CA$38.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
Defence Therapeutics Inc
Glance View
Defence Therapeutics, Inc. engages in the research and development of anti-body drug conjugates. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-05-07. The Company’s principal business activity is the development of a biological drug enhancer platform for biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The firm is engaged in developing the vaccines and antibody drug conjugates (ADC) products. Its Accum Technology platform provides drug delivery enhancements. The firm is focused on infectious disease and virus vaccine development by utilizing its platform for targeted drug delivery and treatments. Accum-T-DM1 is the Company’s product that is in preclinical stage.
See Also
What is Defence Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-3.5m
CAD
Based on the financial report for Jun 30, 2025, Defence Therapeutics Inc's Net Income (Common) amounts to -3.5m CAD.
What is Defence Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-39%
Over the last year, the Net Income (Common) growth was 73%. The average annual Net Income (Common) growth rates for Defence Therapeutics Inc have been 22% over the past three years , -39% over the past five years .
